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Cerebral malaria (CM) is a major complication of
Plasmodium falciparum infection in children. The
pathogenesis of CM involves vascular inflammation,
immune stimulation, and obstruction of cerebral
capillaries. Platelets have a prominent role in both
immune responses and vascular obstruction. We
now demonstrate that the platelet-derived chemo-
kine, platelet factor 4 (PF4)/CXCL4, promotes the
development of experimental cerebral malaria
(ECM). Plasmodium-infected red blood cells (RBCs)
activated platelets independently of vascular effects,
resulting in increased plasma PF4. PF4 or chemokine
receptor CXCR3 null mice had less severe ECM,
including decreased T cell recruitment to the brain,
and platelet depletion or aspirin treatment reduced
the development of ECM. We conclude that Plasmo-
dium-infected RBCs can directly activate platelets,
and platelet-derived PF4 then contributes to immune
activation and T cell trafficking as part of the patho-
genesis of ECM.
INTRODUCTION
Cerebral malaria (CM) is a major complication of Plasmodium fal-
ciparum infection, particularly in children. Thirty-three percent of
children admitted to a hospital in Kenya were reported to have
had malaria, and of these, 47% had neurologic symptoms (Idro
et al., 2007). There were an estimated 515 million clinical
episodes of acute P. falciparum infection in the world in 2002,
mainly affecting children less than 5 years of age, making the
impact of CM staggering (Idro et al., 2007).
CM results from a combination of vascular and immune sys-
tem dysfunction. Brain tissue from patients that die of CM re-
veals multifocal capillary obstruction with parasitized red blood
cells (pRBCs), platelets, and leukocytes (van der Heyde et al.,
2006). Several hypotheses have attempted to explain the noted
pathology. Some view CM as mechanical obstruction of micro-Cell Hvessels, the result of an increase in endothelial cell adhesion
molecule expression and cell attachment (Chakravorty and
Craig, 2005; Tripathi et al., 2006, 2007). Others emphasize an im-
munological basis caused by excessive immune stimulation and
proinflammatory cytokine release (van der Heyde et al., 2006). A
unification of these two ideas includes cell adhesion to the endo-
thelium promoting prothrombotic immune responses, resulting
in further vascular inflammation, immune stimulation, and
obstruction of cerebral capillaries (van der Heyde et al., 2006).
Platelets have a prominent role in both immune responses and
vascular obstruction.
In addition to their vital hemostatic function, platelets are also
active in inflammation. Platelet granules contain many inflamma-
tory and adhesion molecules that are either released or
expressed upon activation. Platelets can interact with an intact
inflamed endothelial cell layer and upon activation initiate inter-
actions with quiescent endothelial and immune cells (Gawaz
et al., 2005). These interactions promote further platelet localiza-
tion and release of more inflammatory molecules setting up a
cycle of continued vascular inflammation (Gawaz et al., 2005).
Platelets are known to contribute to the progression of diverse
vascular and inflammatory diseases and may be involved in
the pathogenesis of CM (Grau et al., 2003; Wassmer et al.,
2003, 2006).
Platelet and RBC aggregates are found in cerebral blood ves-
sels of individuals with fatal malaria (Grau et al., 2003; van der
Heyde et al., 2005). Platelets in coculture with P. falciparum-in-
fected RBCs (PfRBCs) facilitate the binding of PfRBCs to endo-
thelial cells (Wassmer et al., 2004), suggesting a role for platelets
in cooperating with pRBCs to promote cerebral vascular ob-
struction. TNF-a is increased in CM, and TNF-a has recently
been demonstrated to increase platelet binding to the brain mi-
crovasculature in experimental cerebral malaria (ECM) (von Zur
Muhlen et al., 2008), further demonstrating this important
interplay between platelets and immune responses in CM. How-
ever, a direct early effect of infected RBCs on platelets and
platelet-derived mediators in CM immune activation has not
been addressed.
PF4 was the first described CXC class chemokine and is
a platelet granule constituent of great abundance (about 25%
of total alpha granule protein content) (Lambert et al., 2007;ost & Microbe 4, 179–187, August 14, 2008 ª2008 Elsevier Inc. 179
Cell Host & Microbe
PF4 Promotes Cerebral MalariaSachais et al., 2004). Basal PF4 concentration in human plasma
is 2–20 ng/ml but in acute thrombosis has been reported to be
elevated 1000 times to 5–10 mg/ml (Eslin et al., 2004; Sachais
et al., 2004). During acute P. falciparum infection, plasma con-
centrations of PF4 are significantly elevated from a mean con-
trol concentration of 18 ng/ml to greater than 75 ng/ml (Essien
and Ebhota, 1983), demonstrating a potentially significant role
of PF4 in mediating vascular effects in malaria infection. PF4
has many known cell targets including neutrophils, mono-
cytes/macrophages, NK cells, and T cells (Sachais et al.,
2004). PF4 is a ligand for the chemokine receptor CXCR3B
(an alternative splicing variant of CXCR3), a G protein-coupled
receptor expressed on T cells and some endothelial cells (La-
sagni et al., 2003; Mueller et al., 2008; Sachais et al., 2004),
and stimulates neutrophils and macrophages through surface
chondroitin (Boehlen and Clemetson, 2001; von Hundelshau-
sen et al., 2005).
We now demonstrate that the PfRBCs directly activate plate-
lets and the release of the chemokine PF4. PF4 is a mediator of
the pathogenesis of ECM by promoting a proinflammatory envi-
ronment that includes increasing T cell CXCR3 expression and
trafficking to the brain.
Figure 1. Platelets Are Activated by PfRBCs
(A) PfRBCs increase platelet activation; GPIIb/IIIa.
Human platelets were incubated with buffer,
control RBCs, or PfRBCs for 30 min and platelet
activation measured by GPIIb/IIIa receptor activa-
tion (PAC-1 antibody) using flow cytometry. TRAP
(5 mM) treated platelets were used as positive
controls (n = 4, mean ± standard deviation [SD],
*p < 0.01).
(B) P-selectin. Human platelets were incubated
with control RBCs or PfRBCs and surface P-selec-
tin determined using flow cytometry (n = 4, mean ±
SD, *p < 0.03).
(C) PF4 Release. Human platelets were incubated
with buffer solution, control RBCs, or PfRBCs for
30 min and supernatant PF4 measured by ELISA
(n = 4, mean ± SD, *p < 0.01).
(D) PfRBC membranes activate platelets. Control
or PfRBC ghosts were prepared and incubated
with platelets. Platelet activation was determined
by FACS for PAC-1 binding (n = 4, mean ± SD,
*p < 0.01).
(E) PfRBCs activate platelets via CD36. Human
platelets were incubated with control RBCs or
PfRBCs in the presence of control IgG or CD36
blocking antibody Fab fragments for 30 min and
platelet activation determined by FACS (n = 4,
mean ± SD, *p < 0.05).
RESULTS
Platelets Are Activated by PfRBCs
Platelets contribute to CM by promoting
RBC adhesion and vessel obstruction
subsequent to PfRBC-induced vascular
inflammation (Wassmer et al., 2004,
2006). To demonstrate that platelets are
also directly activated by PfRBCs, control
human platelet-rich plasma (PRP) was in-
cubated with purified washed control RBCs, percoll-purified in-
tact trophozoite stage-infected erythrocytes (PfRBCs), or control
buffer. As a positive control comparison, PRP was also treated
with a moderate concentration of a thrombin receptor activating
peptide (TRAP, 5mM). Platelet activation was determined by mea-
suring activated GPIIb/IIIa receptor expression (PAC-1 antibody)
and P-selectin surface expression using flow cytometry. Platelets
incubated with control RBCs had no increase in GPIIb/IIIa activa-
tion (Figure 1A, white versus light gray bars). However, platelets
incubated with PfRBCs had significantly increased PAC-1 ex-
pression (Figure 1A, white versus dark gray bars) and increased
P-selectin expression (Figure 1B). Platelet activation was also de-
termined by measuring PF4 release from PRP incubated with
buffer, control RBCs, or PfRBCs. Plasma PF4 concentration
was similar in platelets incubated with buffer and control RBCs
(Figure 1C, gray versus white bars). PfRBCs, however, stimulated
platelet activation and PF4 release (Figure 1C, black versus gray
bars). Similarly, washed RBCs from C57Bl6/J mice infected with
P. berghei ANKA had increased platelet activation as compared
to platelets incubated with control mouse RBCs (Figure S1 avail-
able online). These data demonstrate that pRBCs can directly
activate platelets.180 Cell Host & Microbe 4, 179–187, August 14, 2008 ª2008 Elsevier Inc.
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PF4 Promotes Cerebral MalariaTo begin to determine how Plasmodium may stimulate platelet
activation we incubated PRP with saponin-purified P. falciparum
trophozoites or purified hemozoin. Neither pure trophozoite nor
hemozoin stimulated platelet activation (data not shown). Puri-
fied membranes (RBC ghosts) from control RBCs or PfRBCs
were also incubated with platelets and platelet activation deter-
mined. Platelets incubated with PfRBC ghosts have significantly
greater platelet activation as compared to platelets incubated
with control RBC ghosts (Figure 1D), demonstrating that PfRBCs
express membrane proteins that are prothrombotic.
PfRBCs can engage CD36 on endothelial cells (Wassmer
et al., 2003). Recently, ligand binding of platelet CD36 has
been shown to stimulate platelet activation (Podrez et al.,
2007). To determine whether PfRBCs stimulate platelet activa-
tion via CD36-mediated signaling, we incubated platelets with
control RBCs or PfRBCs pretreated with Fab fragments of non-
specific IgG or a CD36 blocking antibody. As anticipated,
PfRBCs significantly increased platelet activation (Figure 1E) in
the presence of IgG. However, PfRBCs did not activate platelets
when platelets were pretreated with CD36 blocking antibody
(Figure 1E). These data demonstrate that PfRBCs can stimulate
Figure 2. Platelets Are Activated in ECM
(A) Cerebral thrombi in ECM. P. berghei-infected
mice have cerebral vascular inflammation and
hemorrhage (arrowheads top) and vWf-positive
microvascular thrombi (arrows bottom).
(B) P. berghei-infected mice have increased brain
PF4. Brains were harvested from control and ma-
laria-infected mice on day 5 p.i. PF4 concentration
was determined in brain lysates by ELISA (n = 5,
mean ± SD, *p < 0.01 versus control).
(C) Malaria-infected mice have increased circulat-
ing activated platelets. Platelets from P. berghei-
infected mice were isolated on day 2 and 4 p.i.,
and surface P-selectin and fibrinogen binding
determined by flow cytometry and expressed as
change in fluorescence versus control platelets
(n = 5, mean ± SD, *p < 0.01 versus control).
(D) P. berghei-infected mice have increased
plasma PF4. Plasma from infected and control
mice was isolated and PF4 concentration
determined by ELISA (n = 5 preinfection and day
4, n = 3 day 6, mean ± SD, *p < 0.01 versus prein-
fection).
platelet activation through platelet CD36-
mediated signaling events.
Taken together, these data demon-
strate that PfRBCs directly induce platelet
activation, in part by pRBC interactions
with platelets through a CD36-mediated
mechanism.
Platelets Are Activated Early
in ECM
In the mouse model of CM, P. berghei
ANKA-infected C57Bl6/J mice typically
develop neurological symptoms on day
5 and begin to die day 6 post-infection
(p.i.), with some investigators finding
death rates approaching 90%. To identify cerebral vascular
thrombi as an early component of ECM, control and P. ber-
ghei-infected mice were sacrificed on day 5 p.i., brains isolated,
and histochemistry performed. Using standard hematoxylin and
eosin (H&E) staining, cerebral vessels of control mice had no
inflammatory cells (Figure 2A, top left). Immunohistochemistry
for von Willebrand factor (vWf), a constituent of platelet and
endothelial granules was also performed, and in control mice vWf
is confined to the endothelial cells lining blood vessels
(Figure 2A, bottom left). In contrast, cerebral vessels of P. ber-
ghei-infected mice had multifocal, perivascular hemorrhage, in-
flammatory cell aggregates (Figure 2A, top right), and numerous
vWf-positive thrombi (arrows) lining vessel walls (Figure 2A, bot-
tom right). CD61 (b3 integrin) immunohistochemistry confirms
the presence of nonocclusive adherent immune cells lining cere-
bral blood vessels of P. berghei-infected mice (Figure S2).
Platelet factor 4 (PF4/CXCL4) is a major platelet granule con-
stituent. To further demonstrate that during the development of
ECM there is an increase in platelet cerebral vascular localization
we measured day 5 p.i. whole-brain PF4 concentrations using ly-
sates from homogenized control and P. berghei-infected mice.Cell Host & Microbe 4, 179–187, August 14, 2008 ª2008 Elsevier Inc. 181
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PF4 Promotes Cerebral MalariaPF4 was elevated greater than two times above control levels in
brain lysates from P. berghei infected mice (Figure 2B). These
data clearly demonstrate that platelets are cerebral vascular lo-
calized early in the pathogenesis of ECM.
Platelet activation can exert both local and systemic vascular
immune effects. We therefore next determined the relative in-
crease in circulating activated platelets by comparing infected
mouse platelet P-selectin expression and fibrinogen binding to
control mice using flow cytometry (FACS) on days 2 and 4 p.i.
On day 4 p.i., circulating platelets had an increase in both surface
P-selectin expression and FITC-fibrinogen binding (Figure 2C).
Activated platelets tend to marginate or get cleared from the cir-
culation so a measure of circulating activated platelets under-
represents total platelet activation. To further demonstrate the
potential systemic influence of platelet activation in ECM,
plasma was collected from mice before P. berghei ANKA infec-
tion and again on days 4 and 6 p.i. and PF4 measured by ELISA.
PF4 is elevated more than two times in P. berghei-infected mice
(Figure 2D).
PF4 Helps Drive the Development of ECM
To demonstrate that PF4 is not only a marker of ECM-associated
platelet activation but also a mediator of the pathogenesis of
ECM, we next infected wild-type (WT) and PF4/ mice with P.
berghei. PF4/ mice have been well characterized (Eslin et al.,
2004; Sachais et al., 2007) and have normal complete blood
counts and platelet activation (Table S1 and Figure S3). Addition-
ally, CXCR3/ mice were infected; CXCR3 is a T cell chemokine
receptor recently found necessary for the development of ECM
(Campanella et al., 2008; Miu et al., 2008; Van den Steen et al.,
2008). Infected WT mice began to die on day 6 p.i., and by day
10 only 30% of mice survived (Figure 3A). In contrast, PF4/
mice had equal parasitemia (Figure 3B) but decreased ECM mor-
tality with greater than 60% survival by day 10 p.i. CXCR3/
mice are also protected (Figure 3A). To demonstrate PF4-spe-
cific effects in the PF4 null mice, P. berghei-infected PF4/
mice were given recombinant PF4 (5 mg/mouse) daily. Such ex-
ogenous PF4 restores mortality to levels observed with WT mice
(Figure 3A).
A major step in the pathogenesis of ECM-associated death is
loss of blood brain barrier (BBB) integrity. BBB integrity was de-
termined in WT control and infected WT, PF4/, and CXCR3/
mice by Evans Blue dye extravasation on day 5 p.i. At this early
time point before mice begin to die, WT infected mice already
have an increase in dye extravasation (Figure 3C, black bar). In
contrast, the BBB in PF4/ and CXCR3/ mice is intact and
dye extravasation equal to control uninfected mice (Figure 3C).
Histological examination confirms that PF4/ and CXCR3/
mice have less cerebral vascular inflammation, less hemorrhage,
and fewer microvascular thrombi (Figure 3D). These data dem-
onstrate that PF4 contributes to cerebral vascular damage in
ECM.
If platelets have a role in ECM, then platelet inhibition may
ameliorate cerebral vascular injury associated with Plasmodium
infection. To explore this, beginning 1 day after infection mice
were either platelet depleted or treated with the platelet inhibitors
acetylsalicylic acid (ASA, the active component of aspirin) or Pla-
vix (clopidogrel). Control mice began to die on day 5 with 60%
mortality by day 10 (Figure 3E). Mice treated with platelet inhib-182 Cell Host & Microbe 4, 179–187, August 14, 2008 ª2008 Elsevieitors or platelet depleted had delayed onset of death and only
20% mortality (Figure 3E). Initiation of antiplatelet therapy on
day 3 p.i. did not improve survival (data not shown), indicating
that platelet-mediated effects begin early in the pathogenesis
of ECM.
PF4 Drives ECM-Associated Immune Stimulation
TNF family members TNF-a and lymphotoxin a (LT, also called
TNF-b) are strongly associated with the development of CM
(Hunt and Grau, 2003). TNF-a has recently been demonstrated
to be important in the development of ECM by exerting cerebral
vascular effects that lead to further platelet localization and cere-
bral inflammation (Grau and Lou, 1993; Grau et al., 1993; von Zur
Muhlen et al., 2008). To determine whether PF4 exerts its effects
in part by increasing plasma TNF, TNF-a was measured in con-
trol or infected WT, PF4/, and CXCR3/ mice on day 5 p.i.
TNF-a was elevated in the plasma of WT infected mice on day
5 p.i. (Figure 4A). However, TNF-a was not elevated in P. ber-
ghei-infected PF4/ or CXCR3/ mice (Figure 4A), demon-
strating that PF4 signaling promotes an inflammatory response
to P. berghei including increased TNF-a. IFN-g has also been as-
sociated with ECM (Chakravorty and Craig, 2005; Tripathi et al.,
2006), and its plasma concentrations mirrored that of TNF-a (Fig-
ure 4B).
To determine if increased plasma TNF-a was driven in part by
a direct PF4 effect on immune cells, we first incubated perito-
neal-derived macrophages with control or 1 mg/ml of recombi-
nant PF4 for 48 hr in culture and TNF-a in the supernatant
determined by ELISA. PF4 greatly increased macrophage TNF-
a production in vitro (Figure 4C). We next explored whether
PF4 can also directly stimulate T cell TNF-a production. Spleno-
cytes were isolated and incubated with control or 1 mg/ml of re-
combinant PF4 in anti-CD3-coated wells with anti-CD28 anti-
body for 4 days. TNF-a was increased in the cell culture media
of PF4-treated splenocytes (Figure 4D). IFN-g was unchanged
(data not shown).
CXCR3 has been strongly implicated as a key mediator of
T cell migration to the brain in CM (Campanella et al., 2008; Han-
sen et al., 2007; Miu et al., 2008; Van den Steen et al., 2008). To
determine whether PF4 also contributes to the important in-
crease in CXCR3 T cell response, spleens from control and
infected WT and PF4/ mice were isolated on day 5 p.i. and
T cell CXCR3 expression determined by flow cytometry. The
number of CXCR3-positive CD4+ and CD8+ T cells was more
than doubled in P. berghei-infected WT mice (Figure 4E); how-
ever, T cells from infected PF4/ mice did not have an increase
in CXCR3 expression (Figure 4E). This is in part a direct PF4 ef-
fect. Splenocytes incubated with control or PF4 in anti-CD3-
coated wells with anti-CD28 antibody had an increase in CD4+
and CD8+ T cell CXCR3 surface expression (Figure 4F).
T cell trafficking to the brain is central to the pathogenesis of
CM. On day 5 p.i. brain mononuclear cells were isolated and
T cells quantified to determine whether PF4 mediated an in-
crease in T cell trafficking to the brain in ECM. CD4+ and CD8+
T cells were approximately two times elevated in brains of in-
fected WT mice as compared to uninfected control mice
(Figure 4G, white versus black bars). The number of T cells in
the brains of PF4/ or CXCR3/ mice, however, was not signif-
icantly increased (Figure 4G, white versus dark and light grayr Inc.
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PF4 Promotes Cerebral MalariaFigure 3. PF4 Drives the Development of ECM
(A) PF4 increases ECM. WT, PF4/, CXCR3/, and PF4 reconstituted PF4/mice were infected withP.bergheiand monitored for death (*p < 0.01, log-rank test).
(B) WT and PF4/ P. berghei-infected mice have equal parasite burden (n = 5 days 1–5, n = 3 day 7, mean ± SD).
(C) BBB integrity is protected in PF4/ and CXCR3/ mice. On day 5 p.i., P. berghei-infected and control mice were injected with 200 ml of 2% Evans Blue Dye
IV and dye extravasation determined (n = 5, mean ± SD, *p < 0.05 versus WT).
(D) P. berghei-infected PF4/ and CXCR3/ mice have decreased cerebral vascular damage compared to WT infected mice. H&E top, vWf immunohistochem-
istry bottom.
(E) Platelet inhibition decreases ECM. P. berghei-infected mice were treated with ASA or Plavix/clopidogrel or were platelet depleted (*p < 0.01, log-rank test).bars). Additionally, mice treated with ASA had a decreased num-
ber of brain T cell infiltrates compared to control mice
(Figure 4H). These data demonstrate that platelet activation
and PF4 secretion early in infection are important steps that drive
the ECM T cell response.
DISCUSSION
Here we have shown that PfRBCs directly activated platelets,
that this platelet-activating effect is dependent on platelet
CD36 signaling, and that such activation stimulated the release
of the chemokine PF4. Platelets were activated early in theCell Hopathogenesis of ECM, and platelet inhibition reduced the devel-
opment of ECM. PF4 helps drive ECM in part by increasing TNF
production and T cell trafficking. Thus, PF4 is a key mediator of
the development of ECM.
PF4 stimulated macrophage and T cell TNF-a production.
TNF-a and LTa are key proinflammatory molecules that have
been closely linked to the development of CM (Gimenez et al.,
2003; Lou et al., 1997; Wassmer et al., 2006). TNF-a contributes
to the increased expression of cell adhesion molecules that can
localize immune cells to the cerebral vasculature. Furthermore,
TNF-a has been importantly demonstrated to increase platelet
adhesion to cerebral vasculature (von Zur Muhlen et al., 2008).st & Microbe 4, 179–187, August 14, 2008 ª2008 Elsevier Inc. 183
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PF4 Promotes Cerebral MalariaFigure 4. PF4 Promotes Immune Stimulation and T Cell Trafficking in ECM
(A and B) Plasma TNF-a and IFN-g are not increased in infected PF4/ mice. Plasma was isolated from control or P. berghei-infected mice on day 5 p.i. and (A)
TNF-a and (B) IFN-g concentrations determined by ELISA (n = 5, *p < 0.01 versus WT control).
(C) PF4 increases macrophage TNF-a production. Peritoneal macrophages were incubated with 1 mg of PF4 for 48 hr and TNF-a measured in the culture super-
natant by ELISA (n = 4, mean ± SD, *p < 0.01 versus control).
(D) PF4 increases T cell TNF-a. TNF-a was measured in splenocyte culture supernatants by ELISA (n = 3–6, mean ± SD, *p < 0.01 versus control).
(E) PF4 increases the number of CXCR3-positive T cells in vivo. T cells were isolated from the spleens of P. berghei-infected mice on day 5 p.i. CXCR3 expression
was determined by FACS (n = 5, mean ± SD, *p < 0.01 versus WT control).
(F) PF4 directly increases T cell CXCR3 expression. Splenocytes were incubated in anti-CD3-coated wells with anti-CD28 antibody in the
presence of control or 1 mg/ml of recombinant PF4 for 4 days. CXCR3 surface expression was determined by FACS (n = 4, mean ± SD, *p < 0.05 versus
control).184 Cell Host & Microbe 4, 179–187, August 14, 2008 ª2008 Elsevier Inc.
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inflammatory mediators of platelet activation, immune stimula-
tion, cerebral vascular inflammation, and further platelet cerebral
localization and vascular damage.
Our study helps to extend the role of platelets in CM beyond
vascular contact-dependent mediated effects, to a systemic
proinflammatory role. There has recently been a rapidly ex-
panding appreciation for the wide range of platelet immune
functions and their role in directing immune responses. Platelets
are now known to contribute significantly to the pathogenesis of
diverse diseases such as atherosclerosis (Huo and Ley, 2004),
transplant vasculopathy (Morrell et al., 2007, 2008), and T cell
recruitment in viral hepatitis (Lang et al., 2008). Platelets can
also alter their inflammatory molecule content by rapidly syn-
thesizing protein products, such as IL-1b, in response to stimu-
lation (Denis et al., 2005; Zimmerman and Weyrich, 2008). This
indicates that platelets may alter their inflammatory phenotype
under different environmental conditions. More work is needed
to determine if platelets are not only activated in malaria infec-
tion but also alter their inflammatory phenotype in response to
PfRBCs.
Our studies indicate that platelet-derived PF4 may be a key
player in ECM T cell recruitment. Although PF4 is known to be as-
sociated with thrombosis and the pathogenesis of heparin-in-
duced thrombocytopenia (Eslin et al., 2004), other functions of
PF4 have remained somewhat elusive. PF4 is only now begin-
ning to be associated with other vascular disease processes
that have an inflammatory basis, such as atherosclerosis (Sa-
chais et al., 2007). Our findings demonstrate an important role
for PF4 in ECM that may extend to other vascular diseases
with an immune basis.
CXCR3 has received much recent attention for its role in T cell
trafficking in ECM (Campanella et al., 2008; Miu et al., 2008; Van
den Steen et al., 2008). These important studies highlighted the
critical role of CXCR3 chemokine ligands and CXCR3 signaling in
the pathogenesis of CM. Our work demonstrates an important
connection in ECM between innate platelet-driven immune re-
sponses and T cell responses mediated by PF4-increased
CXCR3 signaling and cerebral localization.
The timing of antiplatelet therapeutic intervention in ECM is im-
portant; we have found that platelet depletion or inhibition on day
3 p.i. offers no help in prolonging the survival of infected mice.
This emphasizes the importance of reducing early platelet acti-
vation to limit a deleterious exaggerated immune response. In-
deed, our data demonstrating that PfRBCs can directly activate
platelets suggest the need for intervention as early as the time
when RBCs first begin to express Plasmodium-derived mole-
cules. We have used the ECM mouse model to demonstrate
that platelet-derived inflammatory molecules such as PF4 con-
tribute greatly to the development of CM. Although theP. berghei
ANKA mouse model recapitulates most aspects of human CM
(van der Heyde et al., 2006), mouse and human immune re-
sponses can differ somewhat, and further study must be under-
taken to determine the role of PF4 in the development of CM.Cell HAn appreciation for platelets as mediators of host immune re-
sponses is a relatively new concept, particularly in the context of
microbial blood-borne pathogens. Our work demonstrates a role
for platelets in directing an immune response toPlasmodium that
leads to the development of CM. Future study is necessary to
evaluate the potential for simple platelet-directed therapeutic
strategies in the prevention of CM.
EXPERIMENTAL PROCEDURES
Reagents
All ELISA kits, recombinant mouse PF4, and CXCR3 antibody were purchased
from R&D systems. Anti-P-selectin, PAC-1, CD4, and CD8 antibodies were
purchased from BD PharMingen. Fibrinogen (Sigma) was FITC (Sigma) labeled
using described methods (Xia et al., 1996). Anti-CD3 and -CD28 antibodies
were purchased from Ebioscience. Fab CD36 antibody fragments were pre-
pared using a Pierce ImmunoPure Fab Preparation kit according to manufac-
turer instructions and CD36 blocking antibody (Santa Cruz).
Ex Vivo Platelet Activation
Percoll-purified washed P. falciparum (clone 3D7) trophozoite stage-infected
RBCs (approximately 94% parasitemia) or control RBCs from the same O+ do-
nor were incubated for 30 min with platelet-rich plasma (PRP) in an approxi-
mately physiologic cell ratio of 10:1 (RBC:platelet) and final volume ratio of
1:1. FITC-PAC-1 antibody (BD PharMingen) was then added for 20 min prior
to fixation with 1% formalin. Washed mouse platelets were isolated as de-
scribed previously (Morrell et al., 2005), and mouse plasma isolated from blood
obtained by retro-orbital bleed into EDTA-coated tubes (BD PharMingen) and
centrifugation. Plasma was incubated with washed platelets for 30 min prior to
incubation with FITC anti-P-selectin antibody. RBC ghosts were prepared as
described by others (Heinz and Hoffman, 1965).
Mouse Studies
Mice were on a C57Bl6 background greater than 10 generations. Mice were
infected with P. berghei ANKA by injection of approximately 0.5 3 106 para-
sites intraperitoneal (IP). Mice were platelet depleted by injection of 100 mg
of anti-GPIb antibody (Emfret) IP, as described previously (Kisucka et al.,
2006), on day 1 p.i. Clopidogrel (Plavix) was injected IP daily (10 mg/kg) and
acetylsalicylic acid (ASA) was provided in the drinking water at 200 mg/l
such that mice receive approximately 500 mg/day. Each treatment was initi-
ated 1 day p.i. Recombinant mouse PF4 was purchased from R&D Systems
and injected intravenously via the retro-orbital plexus.
In Vitro T Cell Culture
For in vitro T cell studies, wells were coated with 0.5 mg/ml of anti-CD3 anti-
body overnight and washed prior to plating splenocytes. Anti-CD28 antibody
(0.5 mg/ml) and recombinant PF4 were added and the media changed replac-
ing PF4 on day 2.
We isolated peritoneal macrophages from C57Bl6/J mice by peritoneal
lavage with saline and plated 1 3 106 cells/well in a 24-well plate for 2 hr.
Nonadherent cells were washed away to eliminate nonmacrophage cells in
the culture. Cells were then incubated with 0 or 1 mg/ml of PF4 for 48 hr, and
the culture supernatant collected and TNF-a production measured by an
ELISA (BioLegend).
Immunohistochemistry was performed using previously published methods,
reagents, and protocols (Yamakuchi et al., 2007).
Brain Mononuclear Cell Isolation
Brain mononuclear cells were isolated by removing brains on day 5 p.i., and
a single-cell suspension obtained by grinding the tissue and mincing it with
a razor blade in Dulbecco-modified Eagle medium with 10% fetal bovine(G) PF4 signaling increases T cell brain infiltration. Brains were isolated and CD8+ and CD4+ T cells determined by FACS (n = 4–5, mean ± SD, *p < 0.05 versus
WT control).
(H) Aspirin-treated mice have fewer T cell infiltrates when P. berghei infected as compared to control infected mice (n = 5, mean ± SD, *p < 0.02 versus WT
control).ost & Microbe 4, 179–187, August 14, 2008 ª2008 Elsevier Inc. 185
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PF4 Promotes Cerebral Malariaserum while on ice. Cell suspensions were placed in 15 ml conical tubes and
Percoll (Sigma) added to a final concentration of 30%. One microliter of Percoll
was underlaid and cells spun at 1300 3 g for 30 min at 4C. Cells at the inter-
face were isolated, washed twice, resuspended in Tyrode’s buffer, and labeled
with anti-CD4 and -CD8 antibodies for flow cytometry.
Blood Brain Barrier Studies
Blood brain barrier permeability was determined by injecting 200 ml of 2%
Evans Blue dye IV into mice on day 5 p.i. One hour later brains were harvested
and incubated in 10% buffered formalin for 48 hr, and dye extravasation deter-
mined by optical density (Gramaglia et al., 2006).
Data Analysis
Data are expressed as means ± standard deviations. Statistical comparisons
between two groups were performed using Student’s t test. Statistics for sur-
vival curves were performed using a log-rank test.
SUPPLEMENTAL DATA
Supplemental Data include five figures and one table and can be found with
this article online at http://www.cellhostandmicrobe.com/cgi/content/full/
4/2/179/DC1/.
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